DESTINY-Breast03 Phase 3 Study Results
Conclusions
Overall health status and QoL was maintained with T-DXd, based on mean change from baseline of
EORTC QLQ-C30 GHS scale (primary PRO variable of interest) and other specified subscales of interest
Median (range) treatment duration was longer in the T-DXd arm (14.3 [0.7-29.8] months) than in the T-DM1
arm (6.9 [0.7-25.1] months)1
For all prespecified PRO variables of interest, the HR for TDD numerically favored T-DXd over T-DM1 (HR
range, 0.69-0.90), indicating T-DXd treatment delays the deterioration of QoL in patients with mBC
•
Delayed TDD of pain symptoms with T-DXd (HR, 0.75) is particularly salient, given its profound
impact on QoL 2,3
Time to first hospitalization was delayed with T-DXd versus T-DM1: median 219.5 days versus 60.0 days,
respectively (interpretation limited by low rates of hospitalization in both arms)
This evidence of maintained QoL while on treatment with T-DXd and delayed definitive deterioration
across prespecified scales versus T-DM1 further supports the improved efficacy (including superior PFS)
and manageable safety profile of T-DXd versus T-DM1,1 thus supporting T-DXd as a standard of care for
patients with HER2+ mBC
EORTC, European Organization for Research and Treatment of Cancer; GHS, global health status; HR, hazard ratio; mBC, metastatic breast cancer; QLQ-C30, Quality of Life Core 30
questionnaire; QoL, quality of life; TDD, time to definitive deterioration; T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan.
Daiichi-Sankyo
1. Cortés J et al. N Engl J Med. 2022;386:1143-1154. 2. Dueñas M, et al. J Pain Res. 2016;9:457–467. 3. Dams L et al. Supportive Care Cancer. 2022; doi: 10.1007/s00520-022-06805-0.
ESMO BC 2022 #1630 Oral
49View entire presentation